SuperworthSpyre Therapeutics shares outstanding SYRE
Diluted shares outstanding, averaged over each quarter, from 2015.
- Latest quarter, to Jun 30, 2026
- 84.7M
- On a year earlier
- +40.4%
- more shares
Spyre Therapeutics had 84.7M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 40.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 75.1M | +36% |
| FY2024 | 55.3M | +254% |
| FY2023 | 15.6M | +310% |
| FY2022 | 3.8M | +44% |
| FY2021 | 2.6M | +1% |
| FY2020 | 2.6M | +97% |
| FY2019 | 1.3M | +38% |
| FY2018 | 957.6K | +44% |
| FY2017 | 662.9K | +24% |
| FY2016 | 533.8K | +2030% |
| FY2015 | 25.1K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 84.7M | +40% | |
| Q1 FY26 | 78.5M | +30% | |
| Q4 FY25 | 75.1M | +36% | |
| Q3 FY25 | 60.4M | +19% | |
| Q2 FY25 | 60.3M | +33% | |
| Q1 FY25 | 60.3M | +65% | |
| Q4 FY24 | 55.3M | +254% | |
| Q3 FY24 | 50.9M | +1085% | |
| Q2 FY24 | 45.3M | +1085% | |
| Q1 FY24 | 36.5M | +868% | |
| Q4 FY23 | 15.6M | +310% | |
| Q3 FY23 | 4.3M | +14% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Spyre Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.